AstraZeneca is interested in partnering opportunities in cardiovascular and gastrointestinal diseases
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
Cardiovascular & Gastrointestinal
AstraZeneca is a world leader in Cardiovascular and Gastrointestinal medicines, committed to delivering new innovative medicines that make a difference to patients and society. Our research focuses on small molecule and biologics for diabetes and diabetic complications, obesity, atherosclerosis, haemostasis, gastrointestinal, abdominal aortic aneurysm, bleeding disorders as well as re-profiling compounds, innovative drug-delivery systems and regenerative medicine.